Results 161 to 170 of about 2,092 (196)

Cerebrolysin for acute ischaemic stroke

Cochrane Database of Systematic Reviews, 2023
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, which has potential neuroprotective properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries.
Liliya Eugenevna, Ziganshina, Tatyana, Abakumova, Dilyara, Nurkhametova, Kristina, Ivanchenko   +3 more
openaire   +2 more sources

Ineffective Drugs: Cerebrolysin and Piracetam

Research Journal of Pharmacy and Technology, 2021
The study of drug efficacy is greatly importance, since the data obtained can be used as a scientific tool for re-evaluating drugs. The aim of the study is to evaluate the efficacy of cerebrolysin and piracetam in patients with acute ischemic stroke. The study included 124 patients with moderate acute ischemic stroke (AIS).
Olga Slyusar, Ivan Maximov, Liudmila Babaskina, Liudmila Lobuteva   +3 more
openaire   +1 more source

Cerebrolysin in Alzheimer's disease

Drugs of Today, 2011
Cerebrolysin is a neuropeptide preparation mimicking the action of endogenous neurotrophic factors. Positive effects of Cerebrolysin on β-amyloid- and tau-related pathologies, neuroinflammation, neurotrophic factors, oxidative stress, excitotoxicity, neurotransmission, brain metabolism, neuroplasticity, neuronal apoptosis and degeneration, neurogenesis
X, Antón Álvarez, Patricio, Fuentes
openaire   +2 more sources

Cerebrolysin for vascular dementia

Cochrane Database of Systematic Reviews, 2010
Vascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention based on its potential neurotrophic and pro-cognitive effects, but studies of its efficacy have yielded inconsistent results.To assess the efficacy and safety of Cerebrolysin for vascular dementia.We searched ALOIS - the Cochrane ...
Ning, Chen, Mi, Yang, Jian, Guo, Muke, Zhou, Cairong, Zhu, Li, He   +5 more
openaire   +2 more sources

Cerebrolysin

Drugs & Aging, 2009
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome ...
Greg L, Plosker, Serge, Gauthier
openaire   +2 more sources

Spotlight on Cerebrolysin in Dementia†

CNS Drugs, 2010
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. In several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome ...
Greg L, Plosker, Serge, Gauthier
openaire   +2 more sources

Cerebrolysin peptides as mood stabilizers

Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2019
To establish the molecular mechanisms of the mood stabilizing (normothymic) action of the neuroprotector Cerebrolysin.Mass-spectrometric analysis of the peptide composition of cerebrolysin followed by a complex bioinformatics analysis was utilized.Cerebrolysin contains considerable amounts of Leu- and Met-enkephalins, partial analogues of enkephalins ...
I Yu, Torshin, O A, Gromova, V G, Zgoda, O V, Tikhonova, S I, Malyavskaya   +4 more
openaire   +2 more sources

[Levamin and cerebrolysin as immunostimulants].

Biulleten' eksperimental'noi biologii i meditsiny, 1992
The experiments on mice have shown that the in vitro treatment of mouse bone marrow cells with levamin or cerebrolysin (amino acids mixture) increased the number of Thy-1 positive cells and stimulated the in vivo immune response to SRBC. Levamin proved more active. At the same time levamin and cerebrolysin had no effect on the immune response to thymus-
G A, Belokrylov, I V, Malchanova
openaire   +3 more sources

Clinical experience with Cerebrolysin®

2000
Cerebrolysin is a peptidergic drug which displays neurotrophic action in various animal models. It is used for the treatment of dementia and in this report we provide evidence for the long-term clinical efficacy of Cerebrolysin in Alzheimer's disease. This evidence is based on our clinical experience with Cerebrolysin, stemming from our participation ...
D W, Molloy, T I, Standish
openaire   +2 more sources

Cerebrolysin in the treatment of cognitive impairment

S.S. Korsakov Journal of Neurology and Psychiatry, 2023
Cognitive impairment is one of the most important problems of modern health care. Currently, according to WHO, more than 55 million people worldwide are living with dementia. Dementia is one of the leading causes of disability and addiction among older people worldwide.
openaire   +2 more sources